Unknown

Dataset Information

0

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.

ABSTRACT: Several anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) have received emergency authorization for coronavirus disease 2019 (COVID-19) treatment. However, most of these mAbs are not active against the highly mutated Omicron SARS-CoV-2 subvariants. We have tested a polyclonal approach of equine anti-SARS-CoV-2 F(ab')2 antibodies that achieved a high level of neutralizing potency against all SARS-CoV-2 variants of concern tested including Omicron BA.1, BA.2, BA.2.12 and BA.4/5. A repertoire of antibodies targeting conserved epitopes in different regions of the spike protein could plausibly account for this remarkable breadth of neutralization. These results warrant the clinical investigation of equine polyclonal F(ab')2 antibodies as a novel therapeutic strategy against COVID-19.

SUBMITTER: Luczkowiak J 

PROVIDER: S-EPMC9384681 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.

Luczkowiak Joanna J   Radreau Pauline P   Nguyen Ludovic L   Labiod Nuria N   Lasala Fátima F   Veas Francisco F   Herbreteau Cécile Hélène CH   Delgado Rafael R  

The Journal of infectious diseases 20221201 1

Several anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) have received emergency authorization for coronavirus disease 2019 (COVID-19) treatment. However, most of these mAbs are not active against the highly mutated Omicron SARS-CoV-2 subvariants. We have tested a polyclonal approach of equine anti-SARS-CoV-2 F(ab')2 antibodies that achieved a high level of neutralizing potency against all SARS-CoV-2 variants of concern tested including Omicron BA.1,  ...[more]

Similar Datasets

Unknown A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
| S-EPMC10469345 | biostudies-literature
Unknown Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern.
| S-EPMC8526700 | biostudies-literature
Unknown Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors.
| S-EPMC7732494 | biostudies-literature
Unknown Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
| S-EPMC10552578 | biostudies-literature
Unknown Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice.
| S-EPMC7106264 | biostudies-literature
Unknown Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
| S-EPMC9187310 | biostudies-literature
Unknown Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
| S-EPMC8928863 | biostudies-literature
Unknown Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination.
| S-EPMC8689782 | biostudies-literature
Genomics Potent neutralizing antibodies against SARS-CoV-2
| EGAS00001004412 | EGA
Unknown Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
| S-EPMC8420542 | biostudies-literature